Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Fransiska Adeline
Indonesia International Institute for Life Sciences (i3L), Jakarta, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Hutchinson Gilford Progeria Syndrome (HGPS): Potential Treatments Dias Rima Sutiono; Fransiska Adeline
Cermin Dunia Kedokteran Vol 45, No 9 (2018): Infeksi
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v45i9.616

Abstract

The Hutchinson-Gilford Progeria syndrome is a rare genetic disease that causes an early accelerated aging in children; clinically characterized by manifestations affecting skin, musculoskeletal system and blood vessels, also other features supporting aging processes. This disease affects 1 in 4 - 8 million newborn all over the world without any race and gender preferences. The clinical features of HGPS usually appear in the age of two and will be discovered through clinical diagnosis. It then will be followed by health problems like coronary atherosclerosis that can be life-threatening. The life-span is usually 14,6 years. This review will discuss some emerging potential treatment such as FTI (Farnesyltransferase inhibitors).Sindrom Hutchinson-Gilford Progeria adalah penyakit genetik langka berupa penuaan lebih cepat pada usia anak-anak ditandai beberapa manifestasi di antaranya kulit, sistem muskuloskeletal dan pembuluh darah, serta hal lain sesuai proses penuaan. Penyakit ini terjadi pada 1 di antara 4-8 juta bayi baru lahir di seluruh dunia tanpa preferensi ras dan gender. Gambaran klinis HGPS biasanya muncul di usia dua tahun, diikuti masalah kesehatan seperti aterosklerosis koroner yang dapat mengancam jiwa. Rentang hidup biasanya 14,6 tahun. Ulasan ini mengenai beberapa pengobatan potensial seperti FTI (inhibitor Farnesyltransferase).
Hutchinson Gilford Progeria Syndrome (HGPS): Potential Treatments Dias Rima Sutiono; Fransiska Adeline
Cermin Dunia Kedokteran Vol 45 No 9 (2018): Infeksi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v50i9.727

Abstract

The Hutchinson-Gilford Progeria syndrome (HGPS) is a rare genetic disease that causes an early accelerated aging in children; clinically characterized by manifestations affecting the skin, musculoskeletal system and blood vessels, also other features supporting aging processes. This disease affects 1 in 4 - 8 million newborns all over the world without any race and gender preferences. The clinical features of HGPS usually appear at the age of two and will be discovered through clinical diagnosis. It then will be followed by health problems like coronary atherosclerosis that can be life-threatening. The life-span is usually 14,6 years. This review will discuss some emerging potential treatment such as FTI (Farnesyltransferase inhibitors). Sindrom Hutchinson-Gilford Progeria adalah penyakit genetik langka berupa penuaan lebih cepat pada usia anak-anak ditandai beberapa manifestasi di antaranya kulit, sistem muskuloskeletal dan pembuluh darah, serta hal lain sesuai proses penuaan. Penyakit ini terjadi pada 1 di antara 4-8 juta bayi baru lahir di seluruh dunia tanpa preferensi ras dan gender. Gambaran klinis HGPS biasanya muncul di usia dua tahun, diikuti masalah kesehatan seperti aterosklerosis pembuluh darah koroner yang dapat mengancam jiwa. Rentang hidup pasien HGPS biasanya 14,6 tahun. Ulasan ini mengenai beberapa pengobatan potensial seperti FTI (inhibitor Farnesyltransferase).
Hutchinson Gilford Progeria Syndrome (HGPS): Potential Treatments Dias Rima Sutiono; Fransiska Adeline
Cermin Dunia Kedokteran Vol 45 No 9 (2018): Infeksi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v50i9.727

Abstract

The Hutchinson-Gilford Progeria syndrome (HGPS) is a rare genetic disease that causes an early accelerated aging in children; clinically characterized by manifestations affecting the skin, musculoskeletal system and blood vessels, also other features supporting aging processes. This disease affects 1 in 4 - 8 million newborns all over the world without any race and gender preferences. The clinical features of HGPS usually appear at the age of two and will be discovered through clinical diagnosis. It then will be followed by health problems like coronary atherosclerosis that can be life-threatening. The life-span is usually 14,6 years. This review will discuss some emerging potential treatment such as FTI (Farnesyltransferase inhibitors). Sindrom Hutchinson-Gilford Progeria adalah penyakit genetik langka berupa penuaan lebih cepat pada usia anak-anak ditandai beberapa manifestasi di antaranya kulit, sistem muskuloskeletal dan pembuluh darah, serta hal lain sesuai proses penuaan. Penyakit ini terjadi pada 1 di antara 4-8 juta bayi baru lahir di seluruh dunia tanpa preferensi ras dan gender. Gambaran klinis HGPS biasanya muncul di usia dua tahun, diikuti masalah kesehatan seperti aterosklerosis pembuluh darah koroner yang dapat mengancam jiwa. Rentang hidup pasien HGPS biasanya 14,6 tahun. Ulasan ini mengenai beberapa pengobatan potensial seperti FTI (inhibitor Farnesyltransferase).
Co-Authors Dias Rima Sutiono